The document discusses recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding meningococcal B (MenB) vaccination. It recommends that adolescents and young adults aged 16-23 receive a MenB vaccine series for short-term protection against most MenB strains. It also recommends MenB vaccination for those aged 10+ who are at increased risk, including those with complement deficiencies or asplenia. The document then discusses how the Trumenba MenB vaccine works by targeting a protein found on over 97% of MenB strains, and that it demonstrated cross-protection against four prevalent MenB strains in clinical trials.

1. Find out here
WELCOME TO
Use your iPad to present
your brand news &
collect customer data !
D E M O P R E S E N TAT I O N
Why MReply is your best brand
partner in digital
communication?

2. Animation
Loop
Animation
Triggering
Navigation in
Presentation
Types of
Answers
What makes MReply unique for consumer?
Additional benefits for your business

3. Your story in pictures with captivating animations and infinite play
before and without user input or any interaction
1A) Animation Loop – Products Rotation

4. slider
900x100
Display and rotate any creative visuals you like:
square ~ slider ~ full-branding ~ pop-up ~ interstitial and more…
1B) Animation Loop - Display Ad Formats
square
300x300

5. 2) Animation Triggering
Let your consumers choose from different products and
expose them to captivating visual content

6. Use inner connections between slides to get to specific
slide
3) Navigation in Slides

7. Scale
option
4A) Options – Single Select
Select option by clicking on images
DRESSES
TOPS JEANS TROUSERS

8. Scale
option
4B) Feedback
Select satisfaction level
DRESSES
How satisfied are you with the product?

9. We will send special prices voucher
SEE YOU ON SEPTEMBER 1st
By clicking Submit, I accept privacy statement
Name
:
Surnam
e:
Phone
:
Email
:
4C) Forms
Fill out forms with intelligent keyboard or by voice

10. 4C) Type of answers
How much do
you like Acidko
yoghurt? (Rank
1-10 )
Describe the taste
with your words
❶
SELECT
❷
INPUT A
❸
INPUT B
4C) Flow
Flow of answers can be easily
designed by your needs
How much do
you like Acidko
yoghurt? (Rank
1-10 )
Describe the taste
with your words
❶
SELECT
❸
INPUT A
❷
INPUT B
Try it out,
tapping on
both of the
bottles

11. Team management
Add your team members and
select user rights (Agent,
Supervisor, …)
Realtime overview of your
team performance
you
supervisor
agent

12. Performance management
Manage your KPIs, compare your team
members performance easily
Agent 2
Agent 1

13. Database + Export
 Direct access to all Q&As for every data input entry
 Ready for your CRM import
 Simple versioning system

14. Customer connectivity
 Further analysis and connectivity
on demand
SMS instant feedback
E-mail messaging
SMS

15. LET’S TALK
ABOUT YOUR
BUSINESS
NEEDS
NOW

16. LET’S TALK ABOUT YOUR BUSINESS NEEDS
SEND
Please, send me examples of latest presentations
THANK
YOU!
We will
help you to
promote
your brand
too!

17. ACIP Recommendations
Support
ACIP recommends that a MenB vaccine series may be administered to adolescents and
young adults aged 16 through 23 years to provide short-term protection against most
strains of MenB disease. The preferred age for MenB vaccination is 16 through 18
years. The decision to vaccinate should be made at the individual level by healthcare
providers.
ACIP recommends certain persons aged ≥10 years who are at increased risk for
meningococcal disease should receive MenB vaccine. These persons include:
• Persons with persistent complement component deficiencies
• Persons with anatomic or functional asplenia, including sickle cell disease
• Microbiologists routinely exposed to isolates of Neisseria meningitidis
• Persons identified as at increased risk because of a MenB disease outbreak
Individuals at increased risk for MenB should be vaccinated, according to ACIP

18. How Trumenba works
Support
TRUMENBA works by targeting both subfamilies, A and B, of a lipoprotein—factor H
binding protein (fHBP)—which is found on more than 97% of all MenB strains.
This method generates antibodies capable of destroying a range of MenB strains.
TRUMENBA targets a protein found in >97% of MenB strains
The fHBP Discovery
Pfizer used a combined biochemical and immunological screening approach to identify
surface-expressed proteins on MenB strains that were capable of producing antibodies
that could kill diverse meningococcal strains. During this process, fHBP elicited robust
bactericidal responses

19. Cross-Coverage
Support
TRUMENBA demonstrated cross-
coverage by targeting MenB
strains expressing both
subfamilies, A and B, of fHBP
TRUMENBA is the only MenB
vaccine that was tested against 4
prevalent strains in the US and
Europe
*In a randomized, placebo-controlled, single-blinded, multicenter trial conducted in Europe, 1713 adolescents 11 through
18 years of age were assigned randomly into 5 groups to receive 2 or 3 doses of TRUMENBA: Group 1 (0, 1, and 6 months);
Group 2 (0, 2, and 6 months); Group 3 (0 and 6 months); Group 4 (0 and 2 months); Group 5 (0 and 4 months).1,2
†To achieve a 4-fold increase in immune response to TRUMENBA, a minimum hSBA (serum bactericidal activity using
human complement) titer of 1:16 was measured if baseline hSBA titer was <1:4; in subjects with a baseline hSBA titer ≥1:4,
an hSBA titer ≥4 times an hSBA titer ≥1:8 (1:16 for strain A22) or ≥4 times the baseline titer, whichever was higher.